Search

Your search keyword '"Dunn, Stephen P"' showing total 771 results
Start Over Author "Dunn, Stephen P"
771 results on '"Dunn, Stephen P"'

1. Outcomes of children with well-differentiated fetal hepatoblastoma treated with surgery only: Report from Childrens Oncology Group Trial, AHEP0731.

Author

Vasudevan, Sanjeev, Meyers, Rebecka, Finegold, Milton, López-Terrada, Dolores, Ranganathan, Sarangarajan, Dunn, Stephen, Langham, Max, McGahren, Eugene, Tiao, Greg, Weldon, Christopher, Krailo, Mark, Piao, Jin, Randazzo, Jessica, Towbin, Alexander, BethMcCarville, M, ONeill, Allison, Furman, Wayne, Rodriguez-Galindo, Carlos, Katzenstein, Howard, and Malogolowkin, Marcio

Subjects
Fetal, Hepatoblastoma, Resection, Well-differentiated, Chemotherapy, Adjuvant, Child, Hepatectomy, Hepatoblastoma, Humans, Infant, Liver Neoplasms, Prognosis, Treatment Outcome
Abstract

BACKGROUND: Hepatoblastoma (HB) requires surgical resection for cure, but only 20-30% of patients have resectable disease at diagnosis. Patients who undergo partial hepatectomy at diagnosis have historically received 4-6 cycles of adjuvant chemotherapy; however, those with 100% well-differentiated fetal histology (WDF) have been observed to have excellent outcomes when treated with surgery alone. PATIENTS AND METHODS: Patients on the Childrens Oncology Group non randomized, multicenter phase III study, AHEP0731, were stratified based on Evans stage, tumor histology, and serum alpha-fetoprotein level at diagnosis. Patients were eligible for the very low risk stratum of surgery and observation if they had a complete resection at diagnosis and rapid central histologic review demonstrated HB with 100% WDF histology. RESULTS: A total of 8 eligible patients were enrolled on study between September 14, 2009 and May 28, 2014. Outcome current to 06/30/2020 was used in this analysis. The median age at enrollment was 22.5 months (range: 8-84 months) and the median AFP at enrollment was 714 ng/ml (range: 18-77,747 ng/mL). With a median follow-up of 6.6 years (range: 3.6-9.8 years), the 5-year event-free (EFS) and overall survival (OS) were both 100%. CONCLUSION: This report supports that HB with 100% WDF histology completely resected at diagnosis is curable with surgery only. The development of evidence-based surgical guidelines utilizing criteria based on PRETEXT group, vascular involvement (annotation factors), tumor-specific histology and corresponding biology will be crucial for optimizing which patients are candidates for resection at diagnosis followed by observation. LEVEL OF EVIDENCE: Prognosis study, Level I evidence.

Published
2022

2. Doxorubicin in combination with cisplatin, 5-flourouracil, and vincristine is feasible and effective in unresectable hepatoblastoma: A Childrens Oncology Group study.

Author

Krailo, Mark, Piao, Jin, Towbin, Alexander, McCarville, M, Tiao, Gregory, Dunn, Stephen, Langham, Max, McGahren, Eugene, Finegold, Milton, Ranganathan, Sarangarajan, Weldon, Christopher, Thompson, Patrick, Trobaugh-Lotrario, Angela, ONeill, Allison, Furman, Wayne, Chung, Nadia, Randazzo, Jessica, Rodriguez-Galindo, Carlos, Meyers, Rebecka, Katzenstein, Howard, and Malogolowkin, Marcio

Subjects
Pretreatment Extent of Disease (PRETEXT), cisplatin, doxorubicin, hepatoblastoma, pediatric liver transplant, pediatric liver tumor, toxicity, Antineoplastic Combined Chemotherapy Protocols, Cisplatin, Doxorubicin, Feasibility Studies, Hepatoblastoma, Humans, Liver Neoplasms, Treatment Outcome, Vincristine
Abstract

BACKGROUND: The Childrens Oncology Group (COG) adopted cisplatin, 5-flourouracil, and vincristine (C5V) as standard therapy after the INT-0098 legacy study showed statistically equivalent survival but less toxicity in comparison with cisplatin and doxorubicin. Subsequent experience demonstrated doxorubicin to be effective in patients with recurrent disease after C5V, and this suggested that it could be incorporated to intensify therapy for patients with advanced disease. METHODS: In this nonrandomized, phase 3 COG trial, the primary aim was to explore the feasibility and toxicity of a novel therapeutic cisplatin, 5-flourouracil, vincristine, and doxorubicin (C5VD) regimen with the addition of doxorubicin to C5V for patients considered to be at intermediate risk. Patients were eligible if they had unresectable, nonmetastatic disease. Patients with a complete resection at diagnosis and local pathologic evidence of small cell undifferentiated histology were also eligible for an assessment of feasibility. RESULTS: One hundred two evaluable patients enrolled between September 14, 2009, and March 12, 2012. Delivery of C5VD was feasible and tolerable: the mean percentages of the target doses delivered were 96% (95% CI, 94%-97%) for cisplatin, 96% (95% CI, 94%-97%) for 5-fluorouracil, 95% (95% CI, 93%-97%) for doxorubicin, and 90% (95% CI, 87%-93%) for vincristine. Toxicity was within expectations, with death as a first event in 1 patient. The most common adverse events were febrile neutropenia (n = 55 [54%]), infection (n = 48 [47%]), mucositis (n = 31 [30%]), hypokalemia (n = 39 [38%]), and elevated aspartate aminotransferase (n = 28 [27%]). The 5-year event-free and overall survival rates for the 93 patients who did not have complete resection at diagnosis were 88% (95% CI, 79%-93%) and 95% (95% CI, 87%-98%), respectively. CONCLUSIONS: The addition of doxorubicin to the previous standard regimen of C5V is feasible, tolerable, and efficacious, and this suggests that C5VD is a good regimen for future clinical trials.

Published
2022

3. Small Cell Undifferentiated Histology Does Not Adversely Affect Outcome in Hepatoblastoma: A Report From the Childrens Oncology Group (COG) AHEP0731 Study Committee.

Author

Trobaugh-Lotrario, Angela, Katzenstein, Howard, Ranganathan, Sarangarajan, Lopez-Terrada, Dolores, Krailo, Mark, Piao, Jin, Chung, Nadia, Randazzo, Jessica, Furman, Wayne, McCarville, Elizabeth, Towbin, Alexander, Tiao, Greg, Dunn, Stephen, Langham, Max, McGahren, Eugene, Feusner, James, Rodriguez-Galindo, Carlos, Meyers, Rebecka, ONeill, Allison, Finegold, Milton, and Malogolowkin, Marcio

Subjects
Adolescent, Antineoplastic Combined Chemotherapy Protocols, Cell Differentiation, Child, Child, Preschool, Disease Progression, Female, Hepatectomy, Hepatoblastoma, Humans, Infant, Infant, Newborn, Liver Neoplasms, Liver Transplantation, Male, Neoplasm Staging, Progression-Free Survival, Retrospective Studies, Risk Assessment, Risk Factors, Time Factors
Abstract

PURPOSE: Small cell undifferentiated (SCU) histology in hepatoblastoma (HB) tumors has historically been associated with a poor prognosis. Tumors from patients enrolled on Childrens Oncology Group (COG) study AHEP0731 underwent institutional and central pathologic review for identification of SCU histology. PATIENTS AND METHODS: Patients with SCU histology identified at the local treating institution who had otherwise low-risk tumors were upstaged to the intermediate-risk treatment stratum, whereas those only identified by retrospective central review were treated per the local institution as low-risk. Patients with otherwise intermediate- or high-risk tumors remained in that treatment stratum, respectively. Central review was to be performed for all tissue samples obtained at any time point. Treatment was per local review, whereas analysis of outcome was based on central review. RESULTS: Thirty-five patients had some elements (1%-25%) of SCU identified on central review of diagnostic specimens. All but two patient tissue sample retained nuclear INI1 expression. The presence of SCU histology did not correlate with age, alpha-fetoprotein level at diagnosis, or sex. The presence of SCU did not affect event-free survival (EFS). EFS at 5 years for patients with low-risk, intermediate-risk, and high-risk with SCU HB was 86% (95% CI, 33 to 98), 81% (95% CI, 57 to 92), and 29% (95% CI, 4 to 61), respectively, compared with EFS at 5 years for patients without SCU enrolled with low-risk, intermediate-risk, and high-risk of 87% (95% CI, 72 to 95), 88% (95% CI, 79 to 94), and 55% (95% CI, 32 to 74; P = .17), respectively. CONCLUSION: The presence of SCU histology in HB does not appear to adversely affect outcome. Future studies should be able to treat patients with SCU HB according to risk stratification without regard to the presence of SCU histology.

Published
2022

4. Critical elements of pediatric liver cancer surgery

Author

Kastenberg, Zachary J., Baertschiger, Reto M., Cuenca, Alex G., Galvan, Nhu Thao Nguyen, Lemoine, Caroline P., Roach, Jonathan P., Walther, Ashley E., Dunn, Stephen P., Goss, John A., Healey, Patrick J., Karpelowsky, Jonathan, Kim, Eugene S., Langham, Max R., Meyers, Rebecka L., Superina, Riccardo A., Tiao, Greg M., Weldon, Christopher B., Bondoc, Alex J., Riehle, Kimberly J., and Vasudevan, Sanjeev A.

Published
2023
Full Text
View/download PDF

5. Evaluation of the diagnostic biopsy approach for children with hepatoblastoma: A report from the children’s oncology group AHEP 0731 liver tumor committee

Author

Weldon, Christopher B, Madenci, Arin L, Tiao, Gregory M, Dunn, Stephen P, Langham, Max R, McGahren, Eugene D, Ranganathan, Sarangarajan, López-Terrada, Dolores H, Finegold, Milton J, Malogolowkin, Marcio H, Piao, Jin, Huang, Li, Krailo, Mark D, Meyers, Rebecka L, and Katzenstein, Howard M

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Digestive Diseases, Liver Disease, Rare Diseases, Cancer, Pediatric, Clinical Research, Pediatric Cancer, Pediatric Research Initiative, Adolescent, Biopsy, Child, Child, Preschool, Female, Hepatoblastoma, Humans, Infant, Laparoscopy, Liver Neoplasms, Male, Neoplasm Staging, Postoperative Hemorrhage, Intraoperative complications, Minimally invasive surgical procedures, Pediatrics, Oncology, Paediatrics and Reproductive Medicine, Clinical sciences, Paediatrics
Abstract

BackgroundThe histopathological assessment of pediatric liver tumors at presentation is critical to establish a diagnosis, guide treatment, and collect appropriate research samples. The purpose of this study was to evaluate complications associated with different approaches to liver biopsy for newly diagnosed hepatoblastoma.MethodsChildren with hepatoblastoma were enrolled on Children's Oncology Group study AHEP0731 (September 2009-March 2012). This analysis evaluated the study cohort of initially unresectable patients who therefore underwent a biopsy procedure at diagnosis. The primary endpoint was clinically significant postbiopsy hemorrhage, defined as requiring red blood cell transfusion.ResultsWe identified 121 children who underwent open (n = 76, 63%), laparoscopic (n = 17, 14%), or percutaneous (n = 28, 23%) liver biopsies. All biopsy procedures yielded adequate tissue for diagnosis. Postbiopsy hemorrhage requiring transfusion occurred after 26% (n = 31) of biopsies. Need for blood product transfusion most frequently occurred following open (n = 27/76, 36%) and laparoscopic (n = 4/17, 24%) biopsies, compared with percutaneous (n = 0/28, 0%) biopsies (p

Published
2020

6. Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial

Author

Katzenstein, Howard M, Langham, Max R, Malogolowkin, Marcio H, Krailo, Mark D, Towbin, Alexander J, McCarville, Mary Beth, Finegold, Milton J, Ranganathan, Sarangarajan, Dunn, Stephen, McGahren, Eugene D, Tiao, Gregory M, O'Neill, Allison F, Qayed, Muna, Furman, Wayne L, Xia, Caihong, Rodriguez-Galindo, Carlos, and Meyers, Rebecka L

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Oncology and Carcinogenesis, Patient Safety, Pediatric, Clinical Trials and Supportive Activities, Pediatric Cancer, Clinical Research, Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Age Factors, Antineoplastic Combined Chemotherapy Protocols, Chemotherapy, Adjuvant, Child, Child, Preschool, Cisplatin, Disease Progression, Female, Fluorouracil, Hepatectomy, Hepatoblastoma, Humans, Infant, Liver Neoplasms, Male, Neoplasm Staging, Progression-Free Survival, Risk Assessment, Risk Factors, Time Factors, United States, Vincristine, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundHepatoblastoma treatment with curative intent requires surgical resection, but only about a third of newly diagnosed patients with hepatoblastoma have resectable disease at diagnosis. Patients who have upfront resection typically receive a total of 4-6 cycles of adjuvant chemotherapy post-surgery, with the combination of cisplatin, fluorouracil, and vincristine. We aimed to investigate whether event-free survival in children with hepatoblastoma who had complete resection at diagnosis could be maintained with two cycles of adjuvant chemotherapy.MethodsIn this Children's Oncology Group, multicentre, phase 3 trial, patients were enrolled in four risk groups on the basis of Evans surgical stage, tumour histology, and levels of α-fetoprotein at diagnosis to receive risk-adapted therapy. Here, we report on the low-risk stratum of the trial. Eligible patients were younger than 21 years and had histologically confirmed, stage I or II hepatoblastoma without 100% pure fetal stage I or small-cell undifferentiated histology; elevated serum α-fetoprotein level (>100 ng/mL); a complete resection at diagnosis; at least 50% Karnofsky (patients >16 years) or Lansky (patients ≤16 years) performance status; and had received no previous chemotherapy or other hepatoblastoma-directed therapy. Patients received two 21-day cycles of cisplatin, fluorouracil, and vincristine within 42 days of resection, consisting of cisplatin (100 mg/m2 per dose or 3·3 mg/kg per dose for children

Published
2019

8. Characterization of Pulmonary Metastases in Children With Hepatoblastoma Treated on Childrens Oncology Group Protocol AHEP0731 (The Treatment of Children With All Stages of Hepatoblastoma): A Report From the Childrens Oncology Group.

Author

ONeill, Allison, Towbin, Alexander, Krailo, Mark, Xia, Caihong, Gao, Yun, McCarville, M, Meyers, Rebecka, McGahren, Eugene, Tiao, Greg, Dunn, Stephen, Langham, Max, Weldon, Christopher, Finegold, Milton, Ranganathan, Sarangarajan, Furman, Wayne, Rodriguez-Galindo, Carlos, Katzenstein, Howard, and Malogolowkin, Marcio

Subjects
Adolescent, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Child, Child, Preschool, Cisplatin, Disease-Free Survival, Doxorubicin, Drug Administration Schedule, Female, Fluorouracil, Hepatoblastoma, Humans, Infant, Irinotecan, Liver Neoplasms, Lung Neoplasms, Male, Pneumonectomy, Prognosis, Tomography, X-Ray Computed, Treatment Outcome, Vincristine
Abstract

Purpose To determine whether the pattern of lung nodules in children with metastatic hepatoblastoma (HB) correlates with outcome. Methods Thirty-two patients with metastatic HB were enrolled on Childrens Oncology Group Protocol AHEP0731 and treated with vincristine and irinotecan (VI). Responders to VI received two additional cycles of VI intermixed with six cycles of cisplatin/fluorouracil/vincristine/doxorubicin (C5VD), and nonresponders received six cycles of C5VD alone. Patients were imaged after every two cycles and at the conclusion of therapy. All computed tomography scans and pathology reports were centrally reviewed, and information was collected regarding lung nodule number, size, laterality, timing of resolution, and pulmonary surgery. Results Among the 29 evaluable patients, only 31% met Response Evaluation Criteria in Solid Tumors (RECIST) for measurable metastatic disease. The presence of measurable disease by RECIST, the sum of nodule diameters greater than or equal to the cumulative cohort median size, bilateral disease, and ≥ 10 nodules were each associated with an increased risk for an event-free survival event ( P = .48, P = .08, P = .065, P = .03, respectively), with nodule number meeting statistical significance. Ten patients underwent pulmonary resection/metastasectomy at various time points, the benefit of which could not be determined because of small patient numbers. Conclusion Children with metastatic HB have a poor prognosis. Overall tumor burden may be an important prognostic factor for these patients. Lesions that fail to meet RECIST size criteria (ie, those < 10 mm) at diagnosis may contain viable tumor, whereas residual lesions at the end of therapy may constitute eradicated tumor/scar tissue. Patients may benefit from risk stratification on the basis of the burden of lung metastatic disease at diagnosis.

Published
2017

9. Upfront window vincristine/irinotecan treatment of high‐risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 study committee

Author

Katzenstein, Howard M, Furman, Wayne L, Malogolowkin, Marcio H, Krailo, Mark D, McCarville, M Beth, Towbin, Alexander J, Tiao, Greg M, Finegold, Milton J, Ranganathan, Sarangarajan, Dunn, Stephen P, Langham, Max R, McGahren, Eugene D, Rodriguez‐Galindo, Carlos, and Meyers, Rebecka L

Subjects
Cancer, Pediatric Cancer, Pediatric, Rare Diseases, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adolescent, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Child, Child, Preschool, Female, Hepatectomy, Hepatoblastoma, Humans, Infant, Irinotecan, Liver Neoplasms, Liver Transplantation, Male, Survival Rate, Vincristine, alpha-Fetoproteins, hepatoblastoma, high-risk, irinotecan, metastatic, Oncology and Carcinogenesis, Public Health and Health Services, Oncology & Carcinogenesis
Abstract

BackgroundThe identification of new therapies for high-risk (HR) hepatoblastoma is challenging. Children's Oncology Group study AHEP0731 included a HR stratum to explore the efficacy of novel agents. Herein, the authors report the response rate to the combination of vincristine (V) and irinotecan (I) and the outcome of patients with high-risk hepatoblastoma.MethodsPatients with newly diagnosed metastatic hepatoblastoma or those with a serum α-fetoprotein (AFP) level 1 log10 ) decline in their AFP level. Responders were to receive 2 additional cycles of VI intermixed with 6 cycles of the combination of cisplatin, doxorubicin, 5-fluorouracil, and vincristine (C5VD). Nonresponders were to receive 6 cycles of C5VD alone.ResultsA total of 32 patients with a median age at diagnosis of 26 months (range, 11-159 months) were enrolled between September 2009 and February 2012. Fourteen of 30 evaluable patients were responders (RECIST and AFP in 6 patients, RECIST only in 3 patients, and AFP only in 5 patients). The median AFP decline after 2 cycles of VI for the entire group was 345,565 ng/mL (85% of the initial AFP). The 3-year event-free and overall survival rates were 49% (95% confidence interval, 30%-65%) and 62% (95% confidence interval, 42%-77%), respectively.ConclusionsThe VI combination appears to have substantial activity against HR hepatoblastoma. The ultimate impact of this regimen in improving the outcomes of children with HR hepatoblastoma remains to be determined. Cancer 2017;123:2360-2367. © 2017 American Cancer Society.

Published
2017

20. Contributors

Author

Abbas, Abbas E., primary, Adams, David B., additional, Aggarwal, Piyush, additional, Ahmed, Bestoun H., additional, Albanese, Craig, additional, Albert, Matthew R., additional, Ali, Abubaker, additional, Alicuben, Evan, additional, Allaix, Marco E., additional, Altman, Ashley, additional, Ando, Hisami, additional, Andolfi, Ciro, additional, Annamalai, Alagappan, additional, Asare, Elliot A., additional, Asti, Emanuele, additional, Auchincloss, Hugh G., additional, Babic, Benjamin, additional, Baker, Talia B., additional, Ball, Chad G., additional, Barbetta, Arianna, additional, Barlow, John M., additional, Barr, Justin, additional, Barreto, Juan Camilo, additional, Barry, Linda, additional, Beal, Eliza W., additional, Beard, Kristin Wilson, additional, Beck, David E., additional, Behrns, Kevin E., additional, Bellevue, Oliver C., additional, Bellorin-Marin, Omar E., additional, Bergman, Jacques, additional, Berry, James, additional, Besselink, Marc G.H., additional, Bharucha, Adil E., additional, Bilchik, Anton J., additional, Bildzukewicz, Nikolai A., additional, Bingham, Jason, additional, Birnbaum, Elisa, additional, Black, Sylvester M., additional, Blackmon, Shanda H., additional, Bleier, Joshua I.S., additional, Bodzin, Adam S., additional, Boland, C. Richard, additional, Bolton, John, additional, Bolton, Nathan, additional, Bonavina, Luigi, additional, Bonds, Morgan, additional, Bouwense, Stefan A.W., additional, Boys, Joshua A., additional, Bravo-Infante, Raquel, additional, Bremner, Ross M., additional, Brenner, Bruce M., additional, Brown, Shaun R., additional, Callery, Mark P., additional, Cameron, John L., additional, Camilleri, Michael, additional, Campbell, Jacob, additional, Cassim, Riaz, additional, Castillo-Angeles, Manuel, additional, Cauley, Christy, additional, Cavaness, Keith M., additional, Cerfolio, Robert J., additional, Champagne, Bradley J., additional, Chandrasoma, Parakrama, additional, Chang, Alex L., additional, Chapman, Christopher G., additional, Chapman, William C., additional, Cheek, Susannah, additional, Chen, Harvey S., additional, Cho, Clifford S., additional, Choi, Eric T., additional, Choi, Eugene A., additional, Chojnacki, Karen A., additional, Choti, Michael A., additional, Christie, Ian, additional, Chua, Heidi, additional, Church, James M., additional, Cioffi, Jessica L., additional, Clark, Susannah, additional, Clavien, Pierre-Alain, additional, Cloud, Adam, additional, Colavita, Paul D., additional, Colquhoun, Steven D., additional, Conway, William, additional, Cools-Lartigue, Jonathan, additional, Coosemans, Willy, additional, Cornwell, Edward E., additional, Costantini, Mario, additional, Coyle, Yvonne, additional, Craig, Daniel A., additional, Croome, Kristopher P., additional, Cullen, Joseph J., additional, D'Andrea, Anthony P., additional, Dassopoulos, Themistocles, additional, Davila, Marta L., additional, Davila, Raquel E., additional, DeMeester, Steven R., additional, DeMeester, Tom R., additional, Dempsey, Daniel T., additional, dePrisco, Gregory, additional, Depypere, Lieven, additional, Dietz, David W., additional, Dillhoff, Mary E., additional, DiNorcia, Joseph, additional, Doane, Stephen M., additional, Dogeas, Epameinondas, additional, Dozois, Eric J., additional, Dumon, Kristoffel, additional, Dunn, Stephen P., additional, Dunst, Christy M., additional, Dussel, John N., additional, Dyer, Matthew, additional, Efron, Jonathan, additional, El-Gohary, Yousef, additional, Lakis, Mustapha El, additional, Ellison, E. Christopher, additional, Ellsmere, James, additional, Essani, Rahila, additional, Evans, Douglas B., additional, Fang, Sandy H., additional, Fasen, Geoffrey, additional, Fernando, Hiran C., additional, Ferri, Lorenzo, additional, Fichera, Alessandro, additional, Finck, Christine, additional, Fisher, Oliver M., additional, Fleshman, James W., additional, Fong, Yuman, additional, Foreman, Michael L., additional, Francone, Todd D., additional, Franko, Edward R., additional, French, Daniel, additional, Fuchs, Hans Friedrich, additional, Fuchs, Karl Hermann, additional, Funaki, Brian, additional, Funk, Geoffrey A., additional, Fusco, Joseph, additional, Gaitonde, Shrawan G., additional, Gajjar, Aakash H., additional, Garcia-Aguilar, Julio, additional, Gearhart, Susan, additional, Geller, David A., additional, Ghobadi, Comeron, additional, Gilbert, Sebastien, additional, Giles, David, additional, Gillaspie, Erin, additional, Girotti, Micah, additional, Gittes, George K., additional, Goodman, Michael D., additional, Gooszen, Hein G., additional, Gores, Gregory J., additional, Griffin, James F., additional, Griffin, S. Michael, additional, Grimm, Leander, additional, Grochola, L.F., additional, Habib, Fahim, additional, Hanks, John B., additional, Harris, James E., additional, Hartwig, Matthew G., additional, Hassan, Imran, additional, Hedrick, Traci L., additional, Hicks, Terry C., additional, Hodin, Richard, additional, Hofstetter, Wayne L., additional, Hogg, Melissa, additional, Hu, Yue-Yung, additional, Hungness, Eric S., additional, Hunt, Steven R., additional, Huseynova, Khumara, additional, Hyman, Neil H., additional, Iannitti, David A., additional, Indes, Jeffrey, additional, Jenkins, Megan, additional, Jensen, Todd, additional, Jeziorczak, Paul M., additional, Jilani, Danial, additional, Jiménez-Toscano, Marta, additional, Jobe, Blair A., additional, Johnston, Lily E., additional, Kahrilas, Peter J., additional, Kalady, Matthew F., additional, Kassira, Noor, additional, Katkhouda, Namir, additional, Katz, Philip O., additional, Keller, Deborah S., additional, Kelley, Matthew P., additional, Kennedy, Gregory D., additional, Kent, Tara Sotsky, additional, Kia, Leila, additional, Kibbe, Melina R., additional, Kim, John, additional, King, Alice, additional, Kiran, Ravi P., additional, Kirton, Orlando C., additional, Klein, Andrew, additional, Klein, Eric N., additional, Kohn, Geoffrey P., additional, Kovell, Robert Caleb, additional, Kozol, Robert, additional, Lacy, Antonio M., additional, Ladner, Daniela P., additional, Lagarde, S.M., additional, Laituri, Carrie A., additional, Landmann, Alessandra, additional, Lee, Janet T., additional, Lee, Lawrence L., additional, Leinicke, Jennifer A., additional, Lerut, Toni, additional, Levi, David M., additional, Li, Chao, additional, Liang, Yu, additional, Lichliter, Andrew H., additional, Lichliter, Warren E., additional, Lightner, Amy L., additional, Lile, Deacon J., additional, Lillemoe, Keith D., additional, Lin, Jules, additional, Lin, Shu S., additional, Lipham, John C., additional, Litle, Virginia R., additional, Lodhia, Nayna A., additional, Longo, Walter E., additional, Lord, Reginald V.N., additional, Louie, Brian E., additional, Low, Donald E., additional, Lowe, Val J., additional, Luc, Jessica G.Y., additional, Luketich, James D., additional, Ma, Yanling, additional, MacCarty, Robert L., additional, MacDonald, Blair, additional, Madoff, Robert D., additional, Magge, Deepa, additional, Maheshwari, Anurag, additional, Mahmoud, Najjia N., additional, Mahvi, David A., additional, Mahvi, David M., additional, Mak, Grace Z., additional, Mansfield, Sara A., additional, Manzano, Maricarmen, additional, Maron, David J., additional, Mathew, Melvy S., additional, Mathis, Kellie L., additional, Matthews, Jeffrey B., additional, McFadden, David W., additional, Merchea, Amit, additional, Messaris, Evangelos, additional, Miller, Daniel L., additional, Miller, Heidi J., additional, Millis, J. Michael, additional, Mittal, Sumeet K., additional, Molena, Daniela, additional, Montgomery, Stephanie C., additional, Moore, Ryan, additional, Morgan, Katherine A., additional, Mortenson, Melinda M., additional, Mulholland, Michael W., additional, Mulvihill, Michael S., additional, Mutch, Matthew, additional, Nafteux, Philippe Robert, additional, Nagaraju, Arun, additional, Nagorney, David M., additional, Nathan, Hari, additional, Natoli, Karen R., additional, Navuluri, Rakesh, additional, Nissen, Nicholas N., additional, Nobel, Tamar B., additional, Noordman, B.J., additional, Norton, Jeffrey A., additional, Novitsky, Yuri W., additional, Nussbaum, Michael S., additional, Nyberg, Scott L., additional, Oelschlager, Brant K., additional, Oh, Daniel S., additional, Otero-Piñeiro, Ana, additional, Oto, Aytekin, additional, Pachter, H. Leon, additional, Paidas, Charles N., additional, Palazzo, Francesco, additional, Paniccia, Alessandro, additional, Papaconstantinou, Harry T., additional, Pappas, Theodore N., additional, Pappou, Emmanouil P., additional, Parikh, Manish, additional, Paruch, Jennifer L., additional, Patel, Asish D., additional, Patel, Mikin, additional, Patti, Marco G., additional, Paulson, Emily Carter, additional, Pawlik, Timothy M., additional, Payne, Isaac, additional, Pemberton, John H., additional, Pendola, Michael, additional, Perez, Alexander, additional, Pernar, Luise I.M., additional, Peters, Walter R., additional, Petrowsky, Henrik, additional, Peyre, Christian G., additional, Phillips, Alexander W., additional, Pillai, Lashmikumar, additional, Plummer, Joseph M., additional, Pointer, David T., additional, Poruk, Katherine E., additional, Posner, Mitchell C., additional, Postier, Russell, additional, Prachand, Vivek N., additional, Pritts, Timothy A., additional, Quatrino, Gregory, additional, Ranka, Sagar, additional, Rattner, David W., additional, Reavis, Kevin M., additional, Reddy, Vikram B., additional, Remzi, Feza H., additional, Ricciardi, Rocco, additional, Rice, Thomas W., additional, Richman, Aaron, additional, Rider, Paul, additional, Roberts, John Paul, additional, Roberts, Patricia L., additional, Roggin, Kevin K., additional, Roll, Garrett Richard, additional, Rona, Kais, additional, Rosen, Charles B., additional, Ross, Samuel Wade, additional, Roth, J. Scott, additional, Rushing, Amy P., additional, Safar, Bashar, additional, Saldinger, Pierre F., additional, Samakar, Kamran, additional, Sandhu, Kulmeet K., additional, Schaheen, Lara W., additional, Schirmer, Bruce, additional, Schneider, Andrew, additional, Schulick, Richard D., additional, Schwab, Ben, additional, Scurci, Stephanie, additional, Senagore, Anthony, additional, Shah, Adil A., additional, Shah, Shimul A., additional, Shames, Brian, additional, Shanmugan, Skandan, additional, Shapiro, David S., additional, Silviera, Matthew, additional, Slakey, Douglas P., additional, Sloan, Joshua, additional, Smallwood, Nathan, additional, Smith, Shane P., additional, Smithers, B. Mark, additional, Smoot, Rory L., additional, Soares, Kevin C., additional, Soffer, Edy, additional, Solomina, Julia, additional, Soper, Nathaniel J., additional, Spechler, Stuart Jon, additional, Sridhar, Praveen, additional, Steele, Scott R., additional, Sternbach, Joel M., additional, Stevenson, Christina E., additional, Strong, Scott A., additional, Sucandy, Iswanto, additional, Sundaram, Magesh, additional, Sundaresan, Sudhir, additional, Swanstrom, Lee L., additional, Sylla, Patricia, additional, Takada, Tadahiro, additional, Talbot, Ethan, additional, Tam, Vernissia, additional, Tamm, Eric P., additional, Tatarian, Talar, additional, Tavakkoli, Ali, additional, Te, Helen S., additional, Teitelbaum, Ezra N., additional, Ternent, Charles A., additional, Thompson, Jon S., additional, Thomson, Iain, additional, Thorson, Alan G., additional, Thorson, Chad M., additional, Totten, Crystal F., additional, Truty, Mark J., additional, Tsai, Susan, additional, Tseng, Jennifer, additional, Tullius, Tom, additional, Tzakis, Andreas G., additional, van Lanschot, J.J.B., additional, van Santvoort, Hjalmar C., additional, Van Veer, Hans, additional, Vega, Jorge A., additional, Velanovich, Vic, additional, Vogler, Sarah A., additional, Wang, Huamin, additional, Ward, Mark A., additional, Warner, Brad W., additional, Warner, Susanne G., additional, Watson, Thomas J., additional, Waxman, Irving, additional, Webster-Lake, Carissa, additional, Wei, Benjamin, additional, Weiser, Martin R., additional, Wells, Dennis, additional, Wells, Katerina, additional, Welton, Mark Lane, additional, Wen, Yuxiang, additional, Wendling, Mark R., additional, Wesson, Hadley K.H., additional, Wexner, Steven D., additional, White, Rebekah R., additional, Whitlow, Charles B., additional, Wijnhoven, B.P.L., additional, Wilkes, Justin, additional, Wilson, Rickesha L., additional, Witkowski, Piotr, additional, Wolfgang, Christopher L., additional, Worrell, Stephanie G., additional, Yang, Jian, additional, Yeo, Charles J., additional, Yeung, Ching, additional, Yung, Evan E., additional, Zafar, Syed Nabeel, additional, Zaninotto, Giovanni, additional, Zeh, Herbert, additional, Zehetner, Joerg, additional, Zenilman, Michael E., additional, Zimmerman, Pamela, additional, and Zuccaro, Gregory, additional

Published
2019
Full Text
View/download PDF

21. Vincristine/irinotecan/temsirolimus upfront window treatment of high‐risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 Study Committee

Author

Thompson, Patrick A., primary, Malogolowkin, Marcio H., additional, Furman, Wayne L., additional, Piao, Jin, additional, Krailo, Mark D., additional, Chung, Nadia, additional, Brock, Lindsay, additional, Towbin, Alexander J., additional, McCarville, Elizabeth B., additional, Finegold, Milton J., additional, Ranganathan, Sarangarajan, additional, Dunn, Stephen P., additional, Langham, Max R., additional, McGahren, Eugene D., additional, Tiao, Gregory M., additional, Weldon, Christopher B., additional, O'Neill, Allison F., additional, Rodriguez‐Galindo, Carlos, additional, Meyers, Rebecka L., additional, and Katzenstein, Howard M., additional

Published
2023
Full Text
View/download PDF

29. The Soviet and the Savage [and Comments and Replies]

Author

Gellner, Ernest, Akhmanova, Olga, Bessac, Frank B., Dragadze, Tamara, Dunn, Stephen P., Fischer, J. L., Halpern, Joel, Krader, Lawrence, Lewis, E. Glyn, MacConaill, M. A., Makarius, Raoul, Newcomer, Peter J., Pershitz, A. I., Petrova-Averkieva, J. P., Sadomskaya, Natalia, Semeka-Pankratov, Elena, and Shimkin, Demitri B.

Published
1975

30. The Crisis in Soviet Ethnography [and Comments]

Author

Tishkov, Valery A., Abrahamian, Levon H., Chichlo, Boris, Dragadze, T., Dunn, Stephen P., Khazanov, Anatoly M., Kozlov, V. I., Kryukov, M. V., Shnirelman, Victor A., Skalnik, Peter, Slezkine, Yuri, and Verdery, Katherine

Published
1992

34. Doxorubicin in combination with cisplatin, 5‐flourouracil, and vincristine is feasible and effective in unresectable hepatoblastoma: A Children's Oncology Group study

Author

Katzenstein, Howard M., primary, Malogolowkin, Marcio H., additional, Krailo, Mark D., additional, Piao, Jin, additional, Towbin, Alexander J., additional, McCarville, M. Beth, additional, Tiao, Gregory M., additional, Dunn, Stephen P., additional, Langham, Max R., additional, McGahren, Eugene D., additional, Finegold, Milton J., additional, Ranganathan, Sarangarajan, additional, Weldon, Christopher B., additional, Thompson, Patrick A., additional, Trobaugh‐Lotrario, Angela D., additional, O’Neill, Allison F., additional, Furman, Wayne L., additional, Chung, Nadia, additional, Randazzo, Jessica, additional, Rodriguez‐Galindo, Carlos, additional, and Meyers, Rebecka L., additional

Published
2021
Full Text
View/download PDF

45. The Wolfson Prize: designing the hospital of the future

Author

Edwards, Nigel, Dunn, Stephen, Barach, Paul, and Vaughan, Louella

Abstract

The 2021 Wolfson Economics Prize asked how new hospitals should be designed to radically improve patient experiences, clinical outcomes, staff wellbeing and integration with wider health and social care. With a major programme to rebuild and renew hospitals in England underway, the Prize offered an opportunity to understand current thinking about hospitals and their future place.

Published
2023
Full Text
View/download PDF

49. Contributors

Author

Abbott, Andrea M., primary, Abcarian, Herand, additional, Abu-Jaish, Wasef, additional, Adams, David B., additional, Adams, Julie E., additional, Akman, Andrew S., additional, Alberts, Steven R., additional, Ando, Hisami, additional, Armstrong, Leonard, additional, Asamoah, Vivian A., additional, Asgeirsson, Theodor, additional, Ashley, Stanley W., additional, Avgerinos, Dimitrios, additional, Bailey, H. Randolph, additional, Bakhtawar, Humayun, additional, Bandla, Santhoshi, additional, Barlow, John M., additional, Baron, Todd H., additional, Andrade, Juan Camilo Barreto, additional, Bathla, Lokesh, additional, Beaty, Jennifer S., additional, Beck, David E., additional, Beddy, David, additional, Beekley, Alec C., additional, Behrns, Kevin E., additional, Ben-David, Kfir, additional, Bergman, Jacques, additional, Besselink, Marc, additional, Bharucha, Adil E., additional, Billeter, Adrian, additional, Black, Sylvester M., additional, Blatnik, Jeffrey A., additional, Bleday, Ronald, additional, Boland, Brendan J., additional, Boley, Scott J., additional, Bonavina, Luigi, additional, Bonin, Eduardo A., additional, Boostrom, Sarah Y., additional, Bower, Thomas C., additional, Brabender, Jan, additional, Brock, Malcolm V., additional, Buckley, Jill C., additional, Bulsiewicz, William J., additional, Burgess, Adele, additional, Burjonrappa, Sathyaprasad C., additional, Caban, Angel M., additional, Call, Jason A., additional, Callery, Mark P., additional, Cameron, John L., additional, Camilleri, Michael, additional, Carne, Peter W.G., additional, Carr, Jennifer C., additional, Paulson, Emily Carter, additional, Cassim, Riaz, additional, Castell, Donald O., additional, Cataldo, Peter, additional, Cemaj, Samuel, additional, Chandrasoma, Parakrama T., additional, Chang, George J., additional, Chaudhry, Vivek, additional, Chen, Herbert, additional, Cho, Clifford S., additional, Choi, Eugene A., additional, Chojnacki, Karen, additional, Choti, Michael A., additional, Christein, John D., additional, Christensen, Donald O., additional, Chukwumah, Chike V., additional, Chun, Albert K., additional, Cima, Robert R., additional, Clark, Clancy J., additional, Clavien, Pierre-Alain, additional, Cohen, Alfred M., additional, Cohen, Jeffrey, additional, Colquhoun, Steven D., additional, Coosemans, Willy, additional, Coppa, Gene F., additional, Cornwell, Edward E., additional, Cortez, Daniel A., additional, Costantini, Mario, additional, Craig, Daniel A., additional, Crookes, Peter F., additional, Cullen, Joseph J., additional, d’Audiffret, Alexandre, additional, Decaluwé, Herbert, additional, Decker, Georges, additional, Dehn, Thomas C.B., additional, De Leyn, Paul, additional, DeMeester, Steven R., additional, DeMeester, Tom R., additional, Demirjian, Aram N., additional, DeRoss, Anthony L., additional, de Santibañes, Eduardo, additional, Donohue, John H., additional, Dozois, Eric J., additional, Dunkin, Brian J., additional, Dunn, Stephen P., additional, Dunst, Christy M., additional, Duranceau, Andre, additional, Durrani, Noreen, additional, Dutkowski, Philipp, additional, Edil, Barish H., additional, Efron, Jonathan E., additional, El-Gohary, Yousef, additional, Ellison, E. Christopher, additional, Engum, Scott A., additional, Enker, Warren E., additional, Etzioni, David A., additional, Evans, Douglas B., additional, Fazio, Victor W., additional, Felix, Edward L., additional, Fink, Aaron S., additional, Fisher, James, additional, Fitzgibbons, Robert J., additional, Fogel, Evan L., additional, Fong, Yuman, additional, Ford, Debra H., additional, Forgione, Patrick, additional, Fortune, John B., additional, Fritze, Danielle M., additional, Fuchs, Karl-Hermann, additional, Funaki, Brian, additional, Gadacz, Thomas R., additional, Galandiuk, Susan, additional, Geller, David, additional, Gittes, George K., additional, Gitzelmann, Christopher A., additional, Godfrey, Tony E., additional, Goldblatt, Matthew I., additional, Gooszen, Hein G., additional, Gores, Gregory J., additional, Govil, Yogesh, additional, Grant, Kimberly, additional, Greer, Sarah E., additional, Grosfeld, Jay L., additional, Guillem, José G., additional, Hagen, Jeffrey A., additional, Hall, Jason F., additional, Hallemeier, Christopher L., additional, Hallowell, Peter T., additional, Harper, Amy P., additional, Hatzaras, Ioannis S., additional, Haut, Elliott R., additional, Havron, William S., additional, Heitmiller, Richard F., additional, Henderson, J. Michael, additional, Herlong, H. Franklin, additional, Hines, O. Joe, additional, Hirashima, Fuyuki, additional, Hofstetter, Wayne L., additional, Hölscher, Arnulf H., additional, Hompes, Roel, additional, Hoppo, Toshitaka, additional, Huber, Philip J., additional, Hull, Tracy, additional, Hungness, Eric S., additional, Hunter, John G., additional, Huprich, James E., additional, Hussain, Hero K., additional, Hyman, Neil, additional, Irani, Jennifer L., additional, Jackson, Emily T., additional, Jacobs, Danny O., additional, Jensen, Eric H., additional, Jephcott, Catherine, additional, Jobe, Blair A., additional, Johnston, Michael, additional, Jorden, Jeffrey, additional, Joyner, Paul, additional, Julien, Lucas A., additional, Kahrilas, Peter J., additional, Kaleya, Ronald, additional, Kashef, Elika, additional, Katz, Philip, additional, Kent, Tara, additional, Khati, Nadia J., additional, King, Jonathan C., additional, Kissane, Nicole A., additional, Klein, Andrew S., additional, Klinger, Dean E., additional, Knight, Jennifer, additional, Koleilat, Issam, additional, Kozol, Robert, additional, Krantz, Seth B., additional, Ladner, Daniela, additional, Langerman, Alexander, additional, Larson, David W., additional, Law, Simon, additional, Lawler, Leo P., additional, Lazaridis, Konstantinos N., additional, Lee, Yi-Horng, additional, Lee, Yoori, additional, Lefèvre, Jérémie H., additional, Lehman, Glen A., additional, Lerut, Toni, additional, Levi, David M., additional, Lidor, Anne, additional, Liebermann-Meffert, Dorothea, additional, Lillegard, Joseph, additional, Lillemoe, Keith D., additional, Litle, Virginia R., additional, Liu, Donald C., additional, Loftus, Edward V., additional, Lopez-Viego, Miguel, additional, Lord, Reginald V.N., additional, Lowe, Val J., additional, Lurje, Georg, additional, Lyons, Calvin, additional, MacCarty, Robert L., additional, Madoff, Robert D., additional, Maheshwari, Anurag, additional, Mahmoud, Najjia N., additional, Mahvi, David M., additional, Malagó, Massimo, additional, Mannal, Patrick, additional, Marohn, Michael R., additional, Maron, David J., additional, Martz, Joseph E., additional, Mathis, Kellie L., additional, Mathisen, Douglas, additional, Matthews, Jeffrey B., additional, McCahill, Laurence E., additional, McClusky, David A., additional, McFadden, David W., additional, McHenry, Lee, additional, McMurrick, Paul J., additional, Mee, Anthony S., additional, Meilahn, John E., additional, Michelassi, Fabrizio, additional, Miller, Robert C., additional, Miller, Thomas A., additional, Millis, J. Michael, additional, Misawa, Ryosuke, additional, Mittal, Sumeet, additional, Molmenti, Ernesto P., additional, Monson, John R.T., additional, Moore, Jesse, additional, Morgan, Katherine A., additional, Morse, Christopher R., additional, Mortensen, Neil J., additional, Mortenson, Melinda M., additional, Moxon, Ruth, additional, Mulholland, Michael W., additional, Nachmany, Ido, additional, Nafteux, Philippe, additional, Nagorney, David M., additional, Nandakumar, Govind, additional, Natarajan, Bala, additional, Nelson, Heidi, additional, Nicastro, Jeffrey M., additional, Nigam, Ankesh, additional, Nissen, Nicholas N., additional, Norton, Jeffrey A., additional, Nussbaum, Michael, additional, Nyberg, Scott, additional, Öberg, Stefan, additional, Oh, Daniel S., additional, Onesti, Jill K., additional, O’Rourke, Robert W., additional, Oto, Aytekin, additional, Otterson, Mary F., additional, Ouellette, James R., additional, Paidas, Charles N., additional, Pandolfino, John E., additional, Papaconstantinou, Harry T., additional, Pappas, Theodore N., additional, Parc, Yann, additional, Parker, Susan C., additional, Patti, Marco G., additional, Pegoli, Walter, additional, Pemberton, John H., additional, Peters, Jeffrey H., additional, Pham, Thai H., additional, Pillai, Lakshmikumar, additional, Pineda, Carlos E., additional, Pitt, Henry A., additional, Ponsky, Jeffrey L., additional, Posner, Mitchell C., additional, Postier, Russel G., additional, Prabhakaran, Sangeetha, additional, Prachand, Vivek N., additional, Que, Florencia G., additional, Radtke, Arnold, additional, Rai, Rudra, additional, Rakinic, Jan, additional, Rattner, David W., additional, Raymond, Daniel P., additional, Rice, Thomas W., additional, Richardson, J. David, additional, Riegler, Martin, additional, Roberts, John Paul, additional, Roberts, Patricia L., additional, Rodeberg, David A., additional, Roggin, Kevin K., additional, Rolandelli, Rolando, additional, Roman, Sabine, additional, Rosato, Ernest L., additional, Rosen, Michael J., additional, Ross, Andrew, additional, Rushing, Amy P., additional, Sabnis, Adheesh, additional, Saclarides, Theodore J., additional, Sagar, Peter M., additional, Sakorafas, George H., additional, Saltz, Leonard B., additional, Sarin, Shawn N., additional, Sarr, Michael G., additional, Sartorelli, Kennith, additional, Savas, Jeannie F., additional, Schirmer, Bruce, additional, Schmid-Tannwald, Christine, additional, Schneider, John G., additional, Schneider, Paul M., additional, Schnelldorfer, Thomas, additional, Schoetz, David J., additional, Schoppmann, Sebastian, additional, Schröder, Wolfgang, additional, Schulick, Richard D., additional, Senagore, Anthony, additional, Sepesi, Boris, additional, Shaheen, Nicholas J., additional, Sherman, Stuart, additional, Silberstein, Irene, additional, Simmang, Clifford L., additional, Singer, George, additional, Slakey, Douglas P., additional, Smith, Jason, additional, Smith, Jessica K., additional, Snyder, Christopher W., additional, Sonnenday, Christopher J., additional, Soper, Nathaniel J., additional, Sotiropoulos, George C., additional, Spechler, Stuart Jon, additional, Stanley, Andrew, additional, Statter, Mindy B., additional, Steele, Kimberley E., additional, Steinhagen, Emily, additional, Stocchi, Luca, additional, Sudakoff, Gary, additional, Sundaram, Abhishek, additional, Sundaram, Magesh, additional, Swanström, Lee L., additional, Swartz, Daniel E., additional, Takada, Tadahiro, additional, Tamm, Eric P., additional, Tavakkolizadeh, Ali, additional, Telford, Gordon L., additional, Thacker, Julie K. Marosky, additional, Theodoropoulos, Dimitra G., additional, Thomas, Michael S., additional, Thorson, Alan G., additional, Thurston, Kristy, additional, Tichansky, David S., additional, Tomizawa, Yutaka, additional, Traverso, L. William, additional, Trus, Thadeus, additional, Tsai, Susan, additional, Tsikitis, Vassiliki Liana, additional, Tsoraides, Steven, additional, Tutuian, Radu, additional, Tzakis, Andreas G., additional, Vallböhmer, Daniel, additional, Raemdonck, Dirk Van, additional, van Santvoort, Hjalmar, additional, Venbrux, Anthony C., additional, Vickers, Selwyn M., additional, Villar, Hugo V., additional, Villegas, Leonardo, additional, Wallace, James R., additional, Wallace, William D., additional, Wang, Huamin, additional, Wang, Kenneth K., additional, Watkins, James L., additional, Watson, Thomas J., additional, Waxman, Irving, additional, Weiser, Martin R., additional, Welch, John, additional, Welton, Mark L., additional, Wexner, Steven D., additional, White, Rebekah R., additional, Wick, Elizabeth C., additional, Wilson, Alison, additional, Winslow, Emily, additional, Witkowski, Piotr, additional, Wolff, Bruce G., additional, Wolfgang, Christopher L., additional, Wong, W. Douglas, additional, Worsey, Jonathan, additional, Wright, Cameron D., additional, Yadav, Bhupender, additional, Yeo, Charles J., additional, Yeung, Trevor M., additional, Yezhelyev, Max, additional, Yoo, Kyo-Sang, additional, You, Yi-Qian Nancy, additional, Young-Fadok, Tonia M., additional, Zacherl, Johannes, additional, Zaninotto, Giovanni, additional, Zeman, Merissa N., additional, Zimmerman, Pamela, additional, and Zuccaro, Gregory, additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results